Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

OBJECTIVE: To report efficacy and safety of galcanezumab in adults with chronic cluster headache. BACKGROUND: Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide and inhibits its biological activity. METHODS: This study comprised a prospective baseline perio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodick, David W, Goadsby, Peter J, Lucas, Christian, Jensen, Rigmor, Bardos, Jennifer N, Martinez, James M, Zhou, Chunmei, Aurora, Sheena K, Yang, Jyun Yan, Conley, Robert R, Oakes, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787002/
https://www.ncbi.nlm.nih.gov/pubmed/32050782
http://dx.doi.org/10.1177/0333102420905321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787002/
https://www.ncbi.nlm.nih.gov/pubmed/32050782
http://dx.doi.org/10.1177/0333102420905321

Ejemplares similares